Building a mechanistic mathematical model of hepatitis C virus entry
暂无分享,去创建一个
Dilyana Mincheva | Christopher J R Illingworth | Mphatso Kalemera | Joe Grove | C. Illingworth | J. Grove | Mphatso D. Kalemera | Dilyana Mincheva
[1] Charles M. Rice,et al. Claudin-1 is a hepatitis C virus co-receptor required for a late step in entry , 2007, Nature.
[2] Charles M. Rice,et al. Role of Scavenger Receptor Class B Type I in Hepatitis C Virus Entry: Kinetics and Molecular Determinants , 2009, Journal of Virology.
[3] Klasse Pj,et al. Molecular determinants of the ratio of inert to infectious virus particles. , 2015 .
[4] Takeru Suzuki,et al. Thermostable hepatitis C virus JFH1-derived variant isolated by adaptation to Huh7.5.1 cells. , 2018, The Journal of general virology.
[5] R. Cortese,et al. The human scavenger receptor class B type I is a novel candidate receptor for the hepatitis C virus , 2002, The EMBO journal.
[6] Jeremie Guedj,et al. Analysis of Hepatitis C Viral Kinetics during Administration of Two Nucleotide Analogues: Sofosbuvir (Gs-7977) and Gs-0938 , 2014, Antiviral therapy.
[7] Q. Sattentau,et al. Conformational changes induced in the human immunodeficiency virus envelope glycoprotein by soluble CD4 binding , 1991, The Journal of experimental medicine.
[8] Alan S. Perelson,et al. Quantifying the Diversification of Hepatitis C Virus (HCV) during Primary Infection: Estimates of the In Vivo Mutation Rate , 2012, PLoS pathogens.
[9] Jean Dubuisson,et al. High Density Lipoproteins Facilitate Hepatitis C Virus Entry through the Scavenger Receptor Class B Type I* , 2005, Journal of Biological Chemistry.
[10] S. Ciesek,et al. Hepatitis C Virus Hypervariable Region 1 Modulates Receptor Interactions, Conceals the CD81 Binding Site, and Protects Conserved Neutralizing Epitopes , 2010, Journal of Virology.
[11] James S. Owen,et al. Scavenger Receptor BI and BII Expression Levels Modulate Hepatitis C Virus Infectivity , 2007, Journal of Virology.
[12] J. Coffin,et al. Binding of more than one Tva800 molecule is required for ASLV-A entry , 2011, Retrovirology.
[13] C. Rice,et al. Understanding the hepatitis C virus life cycle paves the way for highly effective therapies , 2013, Nature Medicine.
[14] Ryoichi Shima,et al. Lipoprotein Receptors Redundantly Participate in Entry of Hepatitis C Virus , 2016, PLoS pathogens.
[15] Stanley M. Lemon,et al. Neutralizing Monoclonal Antibodies against Hepatitis C Virus E2 Protein Bind Discontinuous Epitopes and Inhibit Infection at a Postattachment Step , 2011, Journal of Virology.
[16] Toshiaki Maruyama,et al. Complete Replication of Hepatitis C Virus in Cell Culture , 2005, Science.
[17] Peter D. Kwong,et al. Conformational dynamics of single HIV-1 envelope trimers on the surface of native virions , 2014, Science.
[18] Roslyn M Bill,et al. A new panel of epitope mapped monoclonal antibodies recognising the prototypical tetraspanin CD81 , 2017, Wellcome open research.
[19] J. Ward,et al. Hepatitis C in Injection-Drug Users - A Hidden Danger of the Opioid Epidemic. , 2018, The New England journal of medicine.
[20] Hui Li,et al. Identification, Molecular Cloning, and Analysis of Full-Length Hepatitis C Virus Transmitted/Founder Genotypes 1, 3, and 4 , 2015, mBio.
[21] Harvey Alter,et al. HVR1-mediated antibody evasion of highly infectious in vivo adapted HCV in humanised mice , 2015, Gut.
[22] Johan Neyts,et al. The postbinding activity of scavenger receptor class B type I mediates initiation of hepatitis C virus infection and viral dissemination , 2013, Hepatology.
[23] Alan S. Perelson,et al. Inferring Viral Dynamics in Chronically HCV Infected Patients from the Spatial Distribution of Infected Hepatocytes , 2014, PLoS Comput. Biol..
[24] C. Rice,et al. Cell culture-grown hepatitis C virus is infectious in vivo and can be recultured in vitro. , 2006, Proceedings of the National Academy of Sciences of the United States of America.
[25] Eva Herrmann,et al. The Level of CD81 Cell Surface Expression Is a Key Determinant for Productive Entry of Hepatitis C Virus into Host Cells , 2006, Journal of Virology.
[26] William J. Rice,et al. Ultrastructural analysis of hepatitis C virus particles , 2013, Proceedings of the National Academy of Sciences.
[27] Robert J. Linhardt,et al. Cellular Binding of Hepatitis C Virus Envelope Glycoprotein E2 Requires Cell Surface Heparan Sulfate* , 2003, Journal of Biological Chemistry.
[28] Uwe Carl,et al. Development of the Twin-Strep-tag® and its application for purification of recombinant proteins from cell culture supernatants. , 2013, Protein expression and purification.
[29] R. Bartenschlager,et al. Characterization of the Early Steps of Hepatitis C Virus Infection by Using Luciferase Reporter Viruses , 2006, Journal of Virology.
[30] Kevin W Eliceiri,et al. NIH Image to ImageJ: 25 years of image analysis , 2012, Nature Methods.
[31] Frederik Graw,et al. Modeling Viral Spread. , 2016, Annual review of virology.
[32] N. Dixit,et al. Inhibitors of hepatitis C virus entry may be potent ingredients of optimal drug combinations , 2017, Proceedings of the National Academy of Sciences.
[33] Ralf Bartenschlager,et al. Scavenger receptor class B type I is a key host factor for hepatitis C virus infection required for an entry step closely linked to CD81 , 2007, Hepatology.
[34] Narendra M. Dixit,et al. Viral Kinetics Suggests a Reconciliation of the Disparate Observations of the Modulation of Claudin-1 Expression on Cells Exposed to Hepatitis C Virus , 2012, PloS one.
[35] Jens Bukh,et al. 82 DELETION OF HYPERVARIABLE REGION 1 (HVR1) OF E2 FROM HCV GENOTYPES 1–6 HAS DIFFERENTIAL EFFECT ON INFECTIVITY IN VITRO AND CAUSES INCREASED SUSCEPTIBILITY TO NEUTRALIZATION , 2009 .
[36] A. Perelson,et al. Modelling how ribavirin improves interferon response rates in hepatitis C virus infection , 2004, Nature.
[37] Robyn L. Stanfield,et al. Hepatitis C Virus E2 Envelope Glycoprotein Core Structure , 2013, Science.
[38] A. Nicosia,et al. Hypervariable Region 1 Deletion and Required Adaptive Envelope Mutations Confer Decreased Dependency on Scavenger Receptor Class B Type I and Low-Density Lipoprotein Receptor for Hepatitis C Virus , 2013, Journal of Virology.
[39] Olivier Poch,et al. EGFR and EphA2 are host factors for hepatitis C virus entry and possible targets for antiviral therapy , 2011, Nature Medicine.
[40] Charles M. Rice,et al. Role of SR-BI in HCV entry: kinetics and molecular determinants , 2009 .
[41] Alan S. Perelson,et al. Elucidation of Hepatitis C Virus Transmission and Early Diversification by Single Genome Sequencing , 2012, PLoS pathogens.
[42] Johannes E. Schindelin,et al. Fiji: an open-source platform for biological-image analysis , 2012, Nature Methods.
[43] Frederic D. Bushman,et al. Hepatitis C Virus Transmission Bottlenecks Analyzed by Deep Sequencing , 2010, Journal of Virology.
[44] A. Tarr,et al. The past, present and future of neutralizing antibodies for hepatitis C virus , 2014, Antiviral research.
[45] M. Marsh,et al. The cell biology of receptor-mediated virus entry , 2011, The Journal of cell biology.
[46] Reza Assadi,et al. The global burden of viral hepatitis from 1990 to 2013: findings from the Global Burden of Disease Study 2013 , 2016, The Lancet.
[47] Ralf Bartenschlager,et al. Characterization of Hepatitis C Virus Particle Subpopulations Reveals Multiple Usage of the Scavenger Receptor BI for Entry Steps* , 2012, The Journal of Biological Chemistry.
[48] Alan S. Perelson,et al. Hepatitis C Viral Dynamics in Vivo and the Antiviral Efficacy of Interferon-α Therapy , 1998 .
[49] M. Houghton,et al. Binding of hepatitis C virus to CD81. , 1998, Science.
[50] Shingo Iwami,et al. Reply to Padmanabhan and Dixit: Hepatitis C virus entry inhibitors for optimally boosting direct-acting antiviral-based treatments , 2017, Proceedings of the National Academy of Sciences.
[51] C. Rice,et al. Hepatitis C virus continuously escapes from neutralizing antibody and T-cell responses during chronic infection in vivo. , 2007, Gastroenterology.
[52] E. Settembre,et al. Mechanistic implications for LDL receptor degradation from the PCSK9/LDLR structure at neutral pH , 2011, EMBO reports.
[53] Charles M. Rice,et al. Human broadly neutralizing antibodies to the envelope glycoprotein complex of hepatitis C virus , 2012, Proceedings of the National Academy of Sciences.
[54] Libin Rong,et al. Modeling shows that the NS5A inhibitor daclatasvir has two modes of action and yields a shorter estimate of the hepatitis C virus half-life , 2013, Proceedings of the National Academy of Sciences.
[55] Charles M. Rice,et al. Human occludin is a hepatitis C virus entry factor required for infection of mouse cells , 2009, Nature.
[56] James E Crowe,et al. Synergistic anti-HCV broadly neutralizing human monoclonal antibodies with independent mechanisms , 2017, Proceedings of the National Academy of Sciences.
[57] Michael S. Diamond,et al. A Library of Infectious Hepatitis C Viruses with Engineered Mutations in the E2 Gene Reveals Growth-Adaptive Mutations That Modulate Interactions with Scavenger Receptor Class B Type I , 2016, Journal of Virology.
[58] Jin Zhong,et al. Identification of a Residue in Hepatitis C Virus E2 Glycoprotein That Determines Scavenger Receptor BI and CD81 Receptor Dependency and Sensitivity to Neutralizing Antibodies , 2008, Journal of Virology.
[59] Wensheng Wei,et al. Attachment and Postattachment Receptors Important for Hepatitis C Virus Infection and Cell-to-Cell Transmission , 2017, Journal of Virology.
[60] Q. Ding,et al. The impact of hepatitis C virus entry on viral tropism. , 2014, Cell host & microbe.
[61] P. Klasse,et al. Molecular determinants of the ratio of inert to infectious virus particles. , 2015, Progress in molecular biology and translational science.
[62] Ron O. Dror,et al. Crystal Structure of a Full-Length Human Tetraspanin Reveals a Cholesterol-Binding Pocket , 2016, Cell.
[63] James E Crowe,et al. HCV Broadly Neutralizing Antibodies Use a CDRH3 Disulfide Motif to Recognize an E2 Glycoprotein Site that Can Be Targeted for Vaccine Design. , 2018, Cell host & microbe.
[64] Peter Loppnau,et al. Structure of LIMP-2 provides functional insights with implications for SR-BI and CD36 , 2013, Nature.
[65] Narendra M. Dixit,et al. Mathematical Model of Viral Kinetics In Vitro Estimates the Number of E2-CD81 Complexes Necessary for Hepatitis C Virus Entry , 2011, PLoS Comput. Biol..
[66] G. Randall,et al. Single Particle Imaging of Polarized Hepatoma Organoids upon Hepatitis C Virus Infection Reveals an Ordered and Sequential Entry Process. , 2018, Cell host & microbe.